StockData
Celldex Therapeutics, Inc. logo

Celldex Therapeutics, Inc. (CLDX) stock

CLDXNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 7/30
$28.04−0.55 (-1.92%)

Close on Nov 17, 2026Market cap $2.20BP/E –Yield –

Celldex Therapeutics price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

Celldex Therapeutics's price to sales ratio was 306.5× on Oct 31, 2025, against 208.1× a year earlier. Over the last 5 years it ranged from 7.9× to 476.9×, with a median of 219.4×.

Price to Sales Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2025Oct 31, 2025306.5×+138.4
2024Dec 31, 2024168.1×−261.4
2023Dec 29, 2023429.4×+82.6
2022Jul 29, 2022346.9×+124.4
2021Dec 31, 2021222.5×+69.1
2020Dec 31, 2020153.4×+145.4
2019Dec 31, 20198.0×+5.0
2018Dec 31, 20183.0×−30.6
2017Dec 29, 201733.6×−19.9
2016Dec 30, 201653.5×−245.9
2015Dec 31, 2015299.4×−144.9
2014Sep 30, 2014444.2×+169.2
2013Dec 31, 2013275.1×+234.2
2012Dec 31, 201240.9×+38.3
2011Dec 30, 20112.6×−2.8
2010Dec 31, 20105.4×–

More Celldex Therapeutics figures

See a number that looks wrong?